Síndrome de seno cavernoso secundario a aspergilosis invasiva con afectación carotídea en paciente VIH

Sr. Editor: El síndrome del seno cavernoso (SSC) queda definido por la afectación de 2 o más de los iii, iv, v o vi nervios craneales, secundario a una lesión ocupante de espacio en el seno cavernoso o a un proceso inflamatorio1. La presentación clínica habitual consiste en dolor periorbitario, ptosis, cefalea, diplopía, oftalmoplejía y alteraciones visuales2, 3, 4. Sus causas más habituales son tumores (adenocarcinoma nasofaríngeo, meningioma, linfoma y metástasis), enfermedad vascular (aneurismas, fístulas y trombosis) y enfermedad inflamatoria (síndrome de Tolosa-Hunt, enfermedad por IgG4, sarcoidosis, vasculitis). Aunque menos frecuente, en poblaciones de riesgo destacan las enfermedades infecciosas (tuberculosis, tromboflebitis por Haemophilus influenzae, neurosífilis o mucormicosis en diabéticos). De un modo excepcional, el SSC puede asociarse a aspergilosis invasiva, como el caso que se presenta. Varón de 49 años, con antecedentes de enfermedad pulmonar obstructiva crónica y VIH estadio C3 (140 cél./mm3 CD4), de diagnóstico tardío 3 meses antes del ingreso. Seguía tratamiento regular con bictegravir, emtricitabina y tenofovir alafenamida. Refería cefalea frontoparietal derecha de 6 meses de evolución, habiendo visitado el servicio de urgencias en varias ocasiones, realizándose tomografía computarizada (TC), craneal sin alteraciones. Progresivamente, asoció diplopía y fotofobia. La exploración neurológica objetivó ptosis derecha fluctuante, pupila derecha midriática hiporreactiva y diplopía en todas las direcciones de la mirada con ..

Ischaemic Stroke in the Time of Coronavirus Disease 2019

Each year, between 1.1 and 1.5 million Europeans have a stroke1. Two to three out of 10 patients die as a consequence of it and about one third remains functionally dependent2. As we know, the likelihood of a favourable outcome in this disease relies heavily on patients presenting promptly after symptoms onset and on hospitals providing immediate access to optimized stroke care

Ischaemic stroke in the time of coronavirus disease 2019

Each year, between 1.1 and 1.5 million Europeans have a stroke1. Two to three out of 10 patients die as a consequence of it and about one third remains functionally dependent2. As we know, the likelihood of a favourable outcome in this disease relies heavily on patients presenting promptly after symptoms onset and on hospitals providing immediate access to optimized stroke care

Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke Registry.

COVID-19 related inflammation, endothelial dysfunction and coagulopathy may increase the bleeding risk and lower efficacy of revascularization treatments in patients with acute ischemic stroke. We aimed to evaluate the safety and outcomes of revascularization treatments in patients with acute ischemic stroke and COVID-19. Retrospective multicenter cohort study of consecutive patients with acute ischemic stroke receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021, tested for SARS-CoV-2 infection. With a doubly-robust model combining propensity score weighting and multivariate regression, we studied the association of COVID-19 with intracranial bleeding complications and clinical outcomes. Subgroup analyses were performed according to treatment groups (IVT-only and EVT). Of a total of 15128 included patients from 105 centers, 853 (5.6%) were diagnosed with COVID-19. 5848 (38.7%) patients received IVT-only, and 9280 (61.3%) EVT (with or without IVT). Patients with COVID-19 had a higher rate of symptomatic intracerebral hemorrhage (SICH) (adjusted odds ratio [OR] 1.53; 95% CI 1.16-2.01), symptomatic subarachnoid hemorrhage (SSAH) (OR 1.80; 95% CI 1.20-2.69), SICH and/or SSAH combined (OR 1.56; 95% CI 1.23-1.99), 24-hour (OR 2.47; 95% CI 1.58-3.86) and 3-month mortality (OR 1.88; 95% CI 1.52-2.33).COVID-19 patients also had an unfavorable shift in the distribution of the modified Rankin score at 3 months (OR 1.42; 95% CI 1.26-1.60). Patients with acute ischemic stroke and COVID-19 showed higher rates of intracranial bleeding complications and worse clinical outcomes after revascularization treatments than contemporaneous non-COVID-19 treated patients. Current available data does not allow direct conclusions to be drawn on the effectiveness of revascularization treatments in COVID-19 patients, or to establish different treatment recommendations in this subgroup of patients with ischemic stroke. Our findings can be taken into consideration for treatment decisions, patient monitoring and establishing prognosis